3.84 USD
↘ 0.07 (1.79%)AT CLOSE (11:59 AM EDT)
Galectin Therapeutics Inc.
GALTNASDAQ • USD
3.86
↗ 0.02 (0.39%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
3.86
↗ 0.02 (0.39%)
Market: CLOSED
Galectin Therapeutics Inc. (GALT) trades at $3.84 per share. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (20.2%) and a bullish Golden Cross on the moving averages.
Technical & fundamental data as of Sep 14, 2026.
Open?$3.95
High?$4.09
Low?$3.82
Prev. Close?$3.91
Volume?338.5K
Avg. Volume?354.4K
VWAP?$3.98
Rel. Volume?0.96x
Bid / Ask
Bid?$3.81 × 100
Ask?$3.90 × 1.0K
Spread?$0.09
Midpoint?$3.86
Valuation & Ratios
Market Cap?387.3M
Shares Out?100.8M
Float?43.7M
Float %?66.3%
P/E Ratio?N/A
P/B Ratio?-2.79
EPS?-$0.28
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Employees
9
Market Cap
394.3M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2002-09-04
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD
NORCROSS, GA 30071
Phone: 678-620-3186
NORCROSS, GA 30071
Phone: 678-620-3186
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?19
Piotroski F-Score?0/9Weak
Altman Z-Score?-55.19Distress
Confidence?59%Low
Short InterestSqueeze Risk
Short % of Float?20.78%Squeeze Risk
Short Interest?9.1M
Days to Cover?33.4
Free Float43.7M
Avg Daily Volume272.1K
Settlement Date2026-08-31
Financial Health
Current Ratio?0.10Weak
Quick Ratio?0.10Weak
Cash Ratio?0.09Low
Debt/Equity?-0.24Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?-2.79CHEAP▾
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-26.1CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?20.2%STRONG▾
Peers50
S&P66
ROA?-189.0%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-15889000
Enterprise Value?$407.0M
Fundamentals ratios updated end of day